YanShu Curative Effect on Bone Metastases of Lung Cancer

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-OIC-16008459

Enrollment

Unknown

Registered

2016-05-11

Start date

2016-05-17

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Metastases of Lung Cancer

Interventions

the first-line treatment of Bone metastasis:Compound sophora injection + clinical standard management

the second-line treatment of Bone metastasis:Compound sophora injection + clinical standard management

the first-line treatment of no Bone metastasis:Compound sophora injection + clinical standard management

the second-line treatment of no Bone metastasis:Compound sophora injection + clinical standard management

Eligibility

Sex/Gender

All

Age

20 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. The diagnosis of lung cancer:pathologicalcytology; 2. Bone metastasesX-ray plain filmCTMRIPET-CT; 3. There have been no SRES; 4. KPS>=70; ZPS<=2; 5. First two chemotherapy drugs.

Exclusion criteria

Exclusion criteria: 1. A Chinese medicine allergy; 2. Have symptoms of central nervous system transfer (without symptoms or no symptoms after treatment, can enter the group); 3. control group: use the other traditional Chinese medicine (TCM) preparations.

Design outcomes

Primary

Measure	Time frame
Bone related events;Bone metastasis;Concentration-response relationship;	—

Countries

China

Contacts

Public ContactShi Qingming

Anhui Chest Hospital

shqm0324@163.com+86 13063495524

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026